Skip to content

Ivabradine

FDA-approved product (solution, oral), marketed as Corlanor, Ivabradine Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ivabradine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cardiac preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ivabradine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Preoperative Ivabradine Doses for Hemodynamic Stability in FESS

    NCT07797946 · start 2026-08-01

    Registered record
    Registry ID
    NCT07797946
    Conditions
    Hemodynamic Instability
    Interventions
    Ivabradine 5 mg/5 mg regimen; Ivabradine 5 mg/7.5 mg regimen; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2027-02-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodynamic Instability
    InterventionIvabradine 5 mg/5 mg regimen; Ivabradine 5 mg/7.5 mg regimen; Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting
  • RECOVER-AUTONOMIC Platform Protocol

    NCT06305780 · start 2024-03-11

    Registered record
    Registry ID
    NCT06305780
    Conditions
    Long COVID; Long Covid19; Long Covid-19
    Interventions
    IVIG + Coordinated Care; IVIG Placebo + Coordinated Care; Ivabradine + Coordinated Care; Ivabradine Placebo + Coordinated Care; IVIG + Usual Care; IVIG Placebo + Usual Care; Ivabradine + Usual Care; Ivabradine Placebo + Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-03-11
    Completion
    2025-07-09
    Enrolment
    381

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong COVID; Long Covid19; Long Covid-19
    InterventionIVIG + Coordinated Care; IVIG Placebo + Coordinated Care; Ivabradine + Coordinated Care; Ivabradine Placebo + Coordinated Care +4 more
    PhasePhase 2
    Registry statusCompleted
  • RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

    NCT06305806 · start 2024-03-11

    Registered record
    Registry ID
    NCT06305806
    Conditions
    Long COVID; Long Covid19; Long Covid-19
    Interventions
    Ivabradine; Ivabradine Placebo; Coordinated Care; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-03-11
    Completion
    2025-12-17
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong COVID; Long Covid19; Long Covid-19
    InterventionIvabradine; Ivabradine Placebo; Coordinated Care; Usual Care
    PhasePhase 2
    Registry statusCompleted
  • Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

    NCT05481177 · start 2023-06-14

    Registered record
    Registry ID
    NCT05481177
    Conditions
    Long Haul COVID; Postural Orthostatic Tachycardia Syndrome
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-06-14
    Completion
    2024-09-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong Haul COVID; Postural Orthostatic Tachycardia Syndrome
    InterventionIvabradine
    PhasePhase 4
    Registry statusUnknown
  • Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

    NCT05882708 · start 2023-06-01

    Registered record
    Registry ID
    NCT05882708
    Conditions
    Sepsis; Ivabradine; Hemodynamics; Heart Rate Control
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-06-01
    Completion
    2027-05-31
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Ivabradine; Hemodynamics; Heart Rate Control
    InterventionIvabradine
    PhasePhase 4
    Registry statusRecruiting
  • Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm

    NCT06371222 · start 2023-02-01

    Registered record
    Registry ID
    NCT06371222
    Conditions
    Mitral Stenosis
    Interventions
    Ivabradine; Beta blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-01
    Completion
    2024-02-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMitral Stenosis
    InterventionIvabradine; Beta blocker
    PhasePhase 4
    Registry statusCompleted
  • Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

    NCT05636774 · start 2022-12-12

    Registered record
    Registry ID
    NCT05636774
    Conditions
    Patients With Advanced Cancer Receiving Specialized Palliative Care
    Interventions
    Heart failure medication; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-12-12
    Completion
    2025-03-01
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Advanced Cancer Receiving Specialized Palliative Care
    InterventionHeart failure medication; Placebo
    PhaseNot applicable
    Registry statusCompleted
  • the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome

    NCT05168189 · start 2022-08

    Registered record
    Registry ID
    NCT05168189
    Conditions
    AF - Atrial Fibrillation
    Interventions
    Ivabradine; transthoracic echo; 24 hours holter
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-08
    Completion
    2024-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAF - Atrial Fibrillation
    InterventionIvabradine; transthoracic echo; 24 hours holter
    PhaseNot recorded
    Registry statusUnknown
  • Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

    NCT05594342 · start 2022-07-01

    Registered record
    Registry ID
    NCT05594342
    Conditions
    Heart Failure; Cardiogenic Shock; Ischemic Heart Disease
    Interventions
    Ivabradine 7.5Mg Tab; DOBUTamine Injectable Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-07-01
    Completion
    2023-01-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Cardiogenic Shock; Ischemic Heart Disease
    InterventionIvabradine 7.5Mg Tab; DOBUTamine Injectable Solution
    PhasePhase 3
    Registry statusUnknown
  • Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

    NCT05279651 · start 2022-06-13

    Registered record
    Registry ID
    NCT05279651
    Conditions
    Myocardial Injury After Noncardiac Surgery (MINS); Myocardial Ischemia
    Interventions
    Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-06-13
    Completion
    2026-06-30
    Enrolment
    2,146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Injury After Noncardiac Surgery (MINS); Myocardial Ischemia
    InterventionIvabradine; Placebo
    PhasePhase 3
    Registry statusActive not recruiting
  • Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI

    NCT05348057 · start 2021-08-01

    Registered record
    Registry ID
    NCT05348057
    Conditions
    Cardiovascular Diseases
    Interventions
    Ivabradine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-08-01
    Completion
    2022-09-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionIvabradine
    PhasePhase 4
    Registry statusUnknown
  • Compression Garments in the Community With POTS

    NCT04881318 · start 2021-05-17

    Registered record
    Registry ID
    NCT04881318
    Conditions
    Postural Orthostatic Tachycardia Syndrome
    Interventions
    Waist-High Compression Tights; Abdominal Compression Garments; Medications that modulate heart rate and blood pressure
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-05-17
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostural Orthostatic Tachycardia Syndrome
    InterventionWaist-High Compression Tights; Abdominal Compression Garments; Medications that modulate heart rate and blood pressure
    PhaseNot applicable
    Registry statusRecruiting
  • Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)

    NCT04853797 · start 2021-05-11

    Registered record
    Registry ID
    NCT04853797
    Conditions
    Headache; Migraine Without Aura
    Interventions
    Levcromakalim; Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-05-11
    Completion
    2025-07-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache; Migraine Without Aura
    InterventionLevcromakalim; Ivabradine; Placebo
    PhaseNot applicable
    Registry statusCompleted
  • Ivabradine for Heart Rate Control In Septic Shock

    NCT04031573 · start 2021-02-26

    Registered record
    Registry ID
    NCT04031573
    Conditions
    Septic Shock
    Interventions
    Ivabradine; Ivabradine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-26
    Completion
    2026-04-14
    Enrolment
    429

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionIvabradine; Ivabradine; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Crossover Study of Propranolol vs Ivabradine in POTS

    NCT04186286 · start 2021-02-01

    Registered record
    Registry ID
    NCT04186286
    Conditions
    Postural Tachycardia Syndrome
    Interventions
    Ivabradine 4-week course; Propranolol 4-week course; Placebo 4-week course
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-01
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostural Tachycardia Syndrome
    InterventionIvabradine 4-week course; Propranolol 4-week course; Placebo 4-week course
    PhasePhase 2
    Registry statusRecruiting